| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 10.4B | 171.16 | 19.79 | 6.12% | -8.86% | -9.31% | 12.96% | 1.51 |
| ACADACADIA Pharmaceuticals Inc. | 4.49B | 26.53 | 19.51 | 31.85% | 24.94% | 28.47% | 3.5% | 0.07 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.82B | 22.96 | 17.53 | 23.49% | 37.63% | 23.64% | 8.48% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.1B | 36.41 | 14.51 | 22.8% | 22.48% | 22.23% | 10.43% | 0.28 |
| ALKSAlkermes plc | 5.15B | 31.22 | 14.39 | -6.36% | 22.27% | 19.55% | 7.87% | 0.05 |
| PRTCPureTech Health plc | 463.31M | 19.17 | 9.59 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 540.89M | 21.38 | -1.20 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 361.97M | 2.13 | -1.39 | -178.79% | 0.01 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 2.45M | 8.55M |
| Revenue Growth % | - | - | - | - | - | - | 2.5% |
| Cost of Goods Sold | 1K | 679K | 0 | 0 | 154.44M | 86.77M | 152.41M |
| COGS % of Revenue | - | - | - | - | - | 35.46% | 17.82% |
| Gross Profit | -1K | -679K | 0 | 0 | -154.44M | -84.32M | -143.86M |
| Gross Margin % | - | - | - | - | - | -34.46% | -16.82% |
| Gross Profit Growth % | - | -678% | 1% | - | - | 0.45% | -0.71% |
| Operating Expenses | 22.72M | 35.79M | 61.97M | 167.33M | 60.55M | 42.05M | 56.3M |
| OpEx % of Revenue | - | - | - | - | - | 17.19% | 6.58% |
| Selling, General & Admin | 3.9M | 6.23M | 16.99M | 47.08M | 59.55M | 42.05M | 56.3M |
| SG&A % of Revenue | - | - | - | - | - | 17.19% | 6.58% |
| Research & Development | 18.82M | 29.56M | 44.98M | 120.26M | 155.04M | 86.77M | 152.41M |
| R&D % of Revenue | - | - | - | - | - | 35.46% | 17.82% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -154.04M | -86.77M | -152.41M |
| Operating Income | -22.72M | -35.79M | -61.97M | -167.33M | -214.99M | -126.37M | -200.16M |
| Operating Margin % | - | - | - | - | - | -51.64% | -23.4% |
| Operating Income Growth % | - | -0.58% | -0.73% | -1.7% | -0.28% | 0.41% | -0.58% |
| EBITDA | -22.72M | -35.11M | -61.92M | -167.15M | -214.57M | -125.94M | -199.81M |
| EBITDA Margin % | - | - | - | - | - | -51.47% | -23.36% |
| EBITDA Growth % | - | -0.55% | -0.76% | -1.7% | -0.28% | 0.41% | -0.59% |
| D&A (Non-Cash Add-back) | 1K | 679K | 50K | 182K | 419K | 432K | 358K |
| EBIT | -26.27M | -35.6M | -61.97M | -167.33M | -213.99M | -126.37M | -200.16M |
| Net Interest Income | -35K | 193K | 140K | 0 | 0 | 0 | 17.35M |
| Interest Income | 92K | 193K | 140K | 0 | 0 | 0 | 17.35M |
| Interest Expense | 127K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.68M | 193K | 140K | 271K | 957K | 3.1M | 17.35M |
| Pretax Income | -26.4M | -35.6M | -61.83M | -167.06M | -214.03M | -123.28M | -182.82M |
| Pretax Margin % | - | - | - | - | - | -50.38% | -21.37% |
| Income Tax | 133K | -84K | -8K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.01% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M |
| Net Margin % | - | - | - | - | - | -50.38% | -21.37% |
| Net Income Growth % | - | -0.34% | -0.74% | -1.7% | -0.28% | 0.42% | -0.48% |
| Net Income (Continuing) | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -306.73 | -348.24 | -103.61 | -58.96 | -69.33 | -18.69 | -10.21 |
| EPS Growth % | - | -0.14% | 0.7% | 0.43% | -0.18% | 0.73% | 0.45% |
| EPS (Basic) | -306.73 | -348.24 | -103.61 | -58.96 | -69.33 | -18.69 | -10.21 |
| Diluted Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M |
| Basic Shares Outstanding | 86.51K | 101.97K | 596.68K | 2.83M | 3.07M | 6.59M | 17.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.13M | 45.5M | 302.33M | 287.41M | 110.84M | 84.88M | 404.37M |
| Cash & Short-Term Investments | 17.95M | 44.81M | 296.61M | 275.91M | 100.49M | 81.3M | 392.57M |
| Cash Only | 17.95M | 44.81M | 296.61M | 138.7M | 61.62M | 81.3M | 215.37M |
| Short-Term Investments | 0 | 0 | 0 | 137.21M | 38.87M | 0 | 177.19M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 3.58M | 11.8M |
| Total Non-Current Assets | 703K | 2.2M | 851K | 5.34M | 4.29M | 3.07M | 78.74M |
| Property, Plant & Equipment | 103K | 1.58M | 836K | 4.87M | 3.87M | 2.65M | 1.36M |
| Fixed Asset Turnover | - | - | - | - | - | 0.92x | 6.28x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 600K | 0 | 0 | 0 | 0 | 0 | 76.96M |
| Other Non-Current Assets | 0 | 620K | 15K | 472K | 416K | 416K | 416K |
| Total Assets | 19.83M | 47.69M | 303.18M | 292.75M | 115.13M | 87.95M | 483.11M |
| Asset Turnover | - | - | - | - | - | 0.03x | 0.02x |
| Asset Growth % | - | 1.41% | 5.36% | -0.03% | -0.61% | -0.24% | 4.49% |
| Total Current Liabilities | 5.14M | 6.82M | 15.72M | 38.43M | 34.34M | 15.75M | 37.55M |
| Accounts Payable | 3.39M | 2.67M | 4.09M | 10.78M | 14.67M | 5.82M | 12.53M |
| Days Payables Outstanding | 1000K | 1.43K | - | - | 34.68 | 24.46 | 30 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 1000K | 1000K | 0 |
| Other Current Liabilities | 1.02M | 0 | 0 | 7.18M | 2.8M | 3.7M | 9.37M |
| Current Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x |
| Quick Ratio | 3.72x | 6.67x | 19.23x | 7.48x | 3.23x | 5.39x | 10.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2K | 763K | 0 | 3.5M | 4.68M | 2.53M | 110K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 763K | 0 | 3.5M | 2.5M | 1.37M | 110K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.15M | 7.58M | 15.72M | 41.94M | 39.02M | 18.28M | 37.66M |
| Total Debt | 0 | 1.46M | 763K | 4.31M | 3.5M | 2.5M | 1.37M |
| Net Debt | -17.95M | -43.36M | -295.85M | -134.39M | -58.12M | -78.81M | -214M |
| Debt / Equity | - | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -178.89x | - | - | - | - | - | - |
| Total Equity | 14.68M | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | 445.45M |
| Equity Growth % | - | 1.73% | 6.17% | -0.13% | -0.7% | -0.08% | 5.39% |
| Book Value per Share | 169.72 | 393.36 | 481.76 | 88.62 | 24.77 | 10.57 | 24.88 |
| Total Shareholders' Equity | 14.68M | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | 445.45M |
| Common Stock | 1K | 1K | 4K | 5K | 5K | 13K | 14K |
| Retained Earnings | -41.37M | -81.01M | -149.55M | -316.62M | -530.64M | -653.92M | -836.74M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | 0 | 0 | -176K | -173K | 0 | 654K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.72M | -32.79M | -52.62M | -124.55M | -185.04M | -111.14M | -131.76M |
| Operating CF Margin % | - | - | - | - | - | -45.42% | -15.4% |
| Operating CF Growth % | - | -0.58% | -0.6% | -1.37% | -0.49% | 0.4% | -0.19% |
| Net Income | -26.54M | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M |
| Depreciation & Amortization | 1K | 679K | 50K | 182K | 419K | 432K | 358K |
| Stock-Based Compensation | 579K | 0 | 5.21M | 22.69M | 28.59M | 24.86M | 41.36M |
| Deferred Taxes | 3.65M | 0 | 0 | 2.09M | 0 | 0 | 0 |
| Other Non-Cash Items | 127K | 668K | 696K | 1.41M | 1.75M | -121K | -1.58M |
| Working Capital Changes | 1.46M | 1.38M | 3.24M | 16.13M | -1.78M | -13.03M | 10.92M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.67M | -837K | 960K | 7.27M | 3.89M | -8.86M | 6.71M |
| Cash from Investing | -63K | -103K | 0 | -140.52M | 96.89M | 38.95M | -248.49M |
| Capital Expenditures | -63K | -103K | 0 | -1.05M | -444K | -50K | 0 |
| CapEx % of Revenue | - | - | - | - | - | 0.02% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -139.47M | 97.33M | 0 | 0 |
| Cash from Financing | 37.8M | 59.76M | 304.42M | 107.59M | 10.46M | 91.87M | 514.32M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 88K | 2.63M | 904K | 279K | 2.33M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -20.78M | -32.89M | -52.62M | -125.6M | -185.49M | -111.19M | -131.76M |
| FCF Margin % | - | - | - | - | - | -45.44% | -15.4% |
| FCF Growth % | - | -0.58% | -0.6% | -1.39% | -0.48% | 0.4% | -0.19% |
| FCF per Share | -240.25 | -322.53 | -88.19 | -44.38 | -60.36 | -16.86 | -7.36 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -180.73% | -129.62% | -37.74% | -62.07% | -130.94% | -169.13% | -70.98% |
| Return on Invested Capital (ROIC) | - | - | - | -232.34% | -239.92% | -2140.71% | -135.06% |
| Gross Margin | - | - | - | - | - | -3445.81% | -1681.98% |
| Net Margin | - | - | - | - | - | -5037.88% | -2137.48% |
| Debt / Equity | - | 0.04x | 0.00x | 0.02x | 0.05x | 0.04x | 0.00x |
| Interest Coverage | -178.89x | - | - | - | - | - | - |
| FCF Conversion | 0.78x | 0.92x | 0.85x | 0.75x | 0.86x | 0.90x | 0.72x |
| Revenue Growth | - | - | - | - | - | - | 249.53% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| License | 98.5M | 2.4M | 8.6M |
| License Growth | - | -97.56% | 258.33% |
| Upfront Payment | - | - | 2.6M |
| Upfront Payment Growth | - | - | - |
Praxis Precision Medicines, Inc. (PRAX) reported $7.5M in revenue for fiscal year 2024.
Praxis Precision Medicines, Inc. (PRAX) grew revenue by 249.5% over the past year. This is strong growth.
Praxis Precision Medicines, Inc. (PRAX) reported a net loss of $273.0M for fiscal year 2024.
Praxis Precision Medicines, Inc. (PRAX) has a return on equity (ROE) of -71.0%. Negative ROE indicates the company is unprofitable.
Praxis Precision Medicines, Inc. (PRAX) had negative free cash flow of $228.4M in fiscal year 2024, likely due to heavy capital investments.